Skip to main content
Log in

The Epidemic of Alzheimer’s Disease

How Can We Manage the Costs?

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Alzheimer’s disease is one of several diseases of the elderly that has recently come into prominence for a number of reasons. First, its prevalence is set to increase as a result of the aging of Western populations. Secondly, the use of institutional care has fallen as a result of major policy changes in many countries, and this has caused a shift in the pattern of care for the elderly. Finally, the advent of innovative pharmacotherapy has caused third-party payers and clinicians to question the way in which this disease is best managed.

International epidemiological data for Western populations point to a potentially considerable increase in the prevalence of the disease over the next 2 decades. Although the cost estimates of the disease vary widely among, or indeed, within different Western countries, they may be considerable. It is clear that innovative strategies, e.g. the use of respite care, sheltered housing and pharmacotherapy, might serve to limit the amount of time patients spend in institutional care. Even a small reduction in this form of care might be sufficient to offset the costs of treatment.

What is lacking today are clear demonstrations as to how these new strategies might contribute to the overall management of this complex and multifactorial disease: this should be the joint focus of care providers and the pharmaceutical industry in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III
Fig. 3
Table IV

Similar content being viewed by others

References

  1. Aronson MK, Ooi WL, Geva DL, et al. Age-dependent incidence, prevalence, and mortality in the old. Arch Intern Med 1991; 151: 989–92

    Article  PubMed  CAS  Google Scholar 

  2. Bosanquet N, May J, Johnson N. Alzheimer’s disease in the UK: burden of disease and future care. Health Policy Review No. 12. London: Imperial College of Science and Technology, 1998

    Google Scholar 

  3. Bickel H, Cooper B. Incidence and relative risk of dementia in an urban elderly population: findings of a prospective field study. Psychol Med 1994; 24: 179–92

    Article  PubMed  CAS  Google Scholar 

  4. Rocca WL, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. Ann Neurol 1991; 30: 381–90

    Article  PubMed  CAS  Google Scholar 

  5. Alzheimer’s Disease Society. The Alzheimer’s disease report, caring for dementia today and tomorrow. London: Alzheimer’s Disease Society, 1993

    Google Scholar 

  6. Cavello MC, Fattore G. The economic and social burden of Alzheimer’s disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997; 11 (4): 184–90

    Google Scholar 

  7. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Dis 1997; 11 (6): 135–45

    Google Scholar 

  8. Alzheimer’s Association. Facts and statistics/prevalence [online]. Available from: URL: http://www.alz.org/facts/rtstats.htm [Accessed 1999 Aug 03]

  9. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150 (6): 899–913

    Google Scholar 

  10. US Census Bureau. International Data Base (IDB) [online]. Available from: URL: http://www.census.gov/ipc/www/idbnew.html [Accessed 1999 Aug 05]

  11. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–79

    Article  PubMed  CAS  Google Scholar 

  12. Katzman R, Kawas C. The epidemiology of dementia and Alzheimer’s disease. In: Terry RD, Katzman R, Bick KI, editors. Alzheimer’s disease. New York (NY): Raven Press, 1994: 105–22

    Google Scholar 

  13. Ritchie K, Kildea D. Is senile dementia ‘age-related’ or ageing-related? - evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931–4

    Article  PubMed  CAS  Google Scholar 

  14. Gray A, Fenn P. Alzheimer’s disease: the burden of the illness in England. Health Trends 1993; 25: 31–7

    PubMed  CAS  Google Scholar 

  15. Schneider J, Kavanagh S, Knapp M, et al. Elderly people with advanced cognitive impairment in England: resource use and costs. Aging Soc 1993; 13: 27–59

    Article  Google Scholar 

  16. Ernst RL, Hay J. The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994; 84: 1261–4

    Article  PubMed  CAS  Google Scholar 

  17. Østbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151 (10): 1457–64

    Google Scholar 

  18. Meek PD, McKeithan EK, Schumock GT. Economic considerations in Alzheimer’s disease. Pharmacotherapy 1998; 18 (2): 68s-73s

    PubMed  CAS  Google Scholar 

  19. Souêtre E, Thawaites RMA, Yeardly HL. Economic impact of Alzheimer’s disease in the UK: cost of care and disease severity for non-institutionalised patients with Alzheimer’s disease. Br J Psychiatry 1999; 174: 51–5

    Article  PubMed  Google Scholar 

  20. Greener M. Counting the cost of Alzheimer’s disease. Pharmaceutical Times 1999 May: 19

  21. Hux MJ, O’Brien B, Iskedjian M, et al. Relation between severity of Alzheimer’s disease and costs of caring. Can Med Assoc J 1998; 159: 457–65

    CAS  Google Scholar 

  22. Bosanquet N, Huttin C, Kurz A, et al. Alzheimer’s disease: an international perspective on care delivery. Health Policy Review Paper No. 11. London: Imperial College of Science, Technology and Medicine, University of London, 1997

    Google Scholar 

  23. Portrait of seniors in Canada. Ottawa: Statistics Canada, 1990

  24. Care of elderly: market survey. London: Laing and Buisson, 1995

  25. Pear R. Clinton seeks aid for the care of those with chronic ills. New York Times 1999 Jan 4: A1

    Google Scholar 

  26. Kavanagh S, Schneider J, Knapp M, et al. Elderly people with dementia: costs, effectiveness and balance of care. In: Knapp M, editor. The economic evaluation of mental health care. Aldershot: Arena, 1995: 125–56

    Google Scholar 

  27. Foster RH, Plosker GL. Donepezil: pharmacoeconomic implications of therapy. Pharmacoeconomics 1999; 16 (1): 99–114

    Article  PubMed  CAS  Google Scholar 

  28. O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570–8

    PubMed  Google Scholar 

  29. Kanowski S. Cost benefit evaluation of drug treatment for Alzheimer’s disease. Arch Gerontol Geriatr 1998; Suppl. 6: 275–80

    Google Scholar 

  30. Flicker L. Acetylcholinesterase inhibitors for Alzheimer’s disease. BMJ 1999; 318: 615–6

    Article  PubMed  CAS  Google Scholar 

  31. Donoghue J, Slee A. Can the NHS afford new Alzheimer’s disease treatments? Pharmacists as patient advocates. Pharm J 1998; 260: 84

    Google Scholar 

  32. Alzheimer’s Research Forum [online]. Available from: URL: http://www.alzforum.org/members/research/drugs/index.html [Accessed 1999 Aug 02]

  33. Leon J, Cheng CK, Neumann P. Alzheimer’s disease care: costs and potential savings. Health Affairs 1998; 17 (6): 206–16

    Article  PubMed  CAS  Google Scholar 

  34. Three new Alzheimer’s programs, including respite care begin. Disease Management News 1998 Aug 10; 3–4

    Google Scholar 

  35. Garner P, Godel M. Specialised early care for Alzheimer’s (SPECAL): making a present of the past. Oxford: Oxfordshire Mental Healthcare NHS Trust, 1996

    Google Scholar 

  36. The Paignton and Brixham GP project. Torquay: South Devon Carers Consortium, 1996 Apr [start date]

    Google Scholar 

  37. The Swedish Institute. The health care system in Sweden. Swedish Institute’s fact sheets on Sweden series. Stockholm: The Swedish Institute, 1994 [also available online at http://www.si.se/eng/epubl/epubl.html]

Download references

Acknowledgements

While the authors have conducted sponsored research in the past, the views contained in the current paper are those of the authors for which none of them has received sponsorship.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Neil Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, N., Davis, T. & Bosanquet, N. The Epidemic of Alzheimer’s Disease. Pharmacoeconomics 18, 215–223 (2000). https://doi.org/10.2165/00019053-200018030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018030-00002

Keywords

Navigation